Diagnostic accuracy of ureteroscopic biopsy for upper tract urothelial carcinoma: implications for kidney-sparing therapy selection
In brief
59% of low-grade ureteroscopic biopsies were upgraded on final pathology
In this single-center study, 17 of 29 tumors called low-grade on ureteroscopic biopsy were high-grade after kidney removal; the biopsy's positive predictive value for low-grade disease was just 41.4%. High-grade biopsy results were much more reliable, but these findings in patients who underwent surgery caution against using a low-grade result alone to select kidney-sparing treatment.
- Journal
- Surgical endoscopy (Q1)
- Published
- 9 October 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Jungwon Park, Jungkeun Song, Younsoo Chung, Hyung Joon Kim, Hakmin Lee, Jong Jin Oh, et al.
- PMID
- 42855510
- DOI
- 10.1007/s00464-026-13249-8
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (top studies of the week, 11 October 2026): URS biopsy accuracy impacts kidney-sparing therapy selection
Abstract
BACKGROUND: Radical nephroureterectomy (RNU) remains the gold standard for high-risk upper tract urothelial carcinoma (UTUC). However, renal preservation is increasingly emphasized for patients with low-grade disease or impaired renal function. OBJECTIVE: To evaluate the diagnostic performance of URS biopsy compared to final pathologic findings after radical nephroureterectomy and to assess the clinical implications for treatment selection. MATERIALS & METHODS: We retrospectively analyzed 913 patients who underwent radical nephroureterectomy for UTUC at a single tertiary center. Among these, 164 patients underwent preoperative URS with biopsy, and 125 had both URS grade and final pathologic grade available for concordance analysis. Diagnostic performance metrics including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Cohen's kappa coefficient were calculated. Risk factors for undergrading were identified using multivariable logistic regression. RESULTS: The overall concordance between URS biopsy and final pathology was 82.4% (103/125). However, marked discordance was observed in low-grade URS biopsies, with an undergrading rate of 58.6% (17/29 cases upgraded to high-grade on final pathology). The PPV for low-grade URS biopsy was only 41.4%, whereas the PPV for high-grade URS biopsy was excellent at 94.8%. Cohen's kappa was 0.423, indicating moderate agreement. Risk factors for undergrading included age <65 years (OR 2.66, p = 0.004), renal pelvis location (OR 2.59, p = 0.037), and multifocal disease (OR 2.12, p = 0.044). Patients undergoing URS biopsy had higher bladder recurrence rates (29.8% vs. 22.3% vs. 20.5%, p = 0.020) despite not being an independent predictor at multivariate analysis (p = 0.289). CONCLUSION: URS biopsy demonstrates high undergrading rates (58.6%) and low PPV (41.4%) for low-grade tumors, making it unreliable for selecting patients for kidney-sparing ablative therapies. High-grade URS biopsies reliably predict high-grade disease. Alternative risk stratification strategies are needed to safely identify candidates for nephron-sparing approaches.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.